5302392026-01-012026-03-315302392026-03-315302392025-03-315302392025-04-012026-03-315302392026-01-012026-03-31in-capmkt:OtherExpenses1Member5302392026-01-012026-03-31in-capmkt:OtherExpenses2Member5302392025-04-012026-03-31in-capmkt:OtherExpenses1Member5302392025-04-012026-03-31in-capmkt:OtherExpenses2Member5302392026-03-31OtherNoncurrentFinancialAssetsDomain15302392026-03-31OtherNoncurrentFinancialAssetsDomain25302392026-03-31OtherNoncurrentAssetsDomain15302392026-03-31OtherCurrentFinancialAssetsDomain15302392026-03-31OtherCurrentFinancialAssetsDomain25302392026-03-31OtherCurrentAssetsDomain15302392026-03-31OtherCurrentFinancialLiabilitiesDomain15302392026-03-31OtherCurrentFinancialLiabilitiesDomain25302392026-03-31OtherCurrentLiabilitiesDomain15302392026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15302392025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15302392026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares530239SUVENNOTLISTEDINE495B01038SUVEN LIFE SCIENCES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-132026-05-06INRLakhsQuarterlyFourth quarterSingle segmentThe Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented2026-05-1312:30:002026-05-1313:30:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31UnauditedConsolidated15201000677780008297900000058289000157800015825000463242000538934000-4559550000-4559550000000-4559550000000-455955000-4666000-4606210002637200001-2.02-2.0200-2.02-2.021) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 13, 2026. The results for the year ended March 31, 2026 has been audited and for the quarter ended March 31, 2026 has been reviewed by our statutory auditors <BR> 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. <BR> 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc. <BR> 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. <BR> 5.1) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination & Remuneration Committee on May 6, 2024. <BR> 5.2) ESOP: for the quarter ended March 31, 2026, the Company recognized an employee benefit expense (EBP) of Rs. 99.25 lakhs in accordance with Ind AS 102 – Share-based Payment. The cumulative EBP recognized as of March 2026 amounts to Rs.178.69 lakhs. <BR> 6) Preferential Issue: The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025. <BR> <BR> Each warrant is convertible into one equity share of face value Rs.1/- at an exercise price of Rs. 134/- per share, within a period of 18 months from the date of allotment. <BR> <BR> Out of the Issue proceeds of Rs.85,764 Lakhs, Rs.76433 Lakhs has been received and Rs. 9331Lakhs is yet to be received from warrant holders. During the period from July 25 to March 26 the Company has allotted 45432866 equity shares on a preferential basis upon conversion of equivalent number of fully paid warrants to six allottees, upon receipt of 100% of the warrant consideration amounting to Rs.60,880.04 lakhs. <BR> <BR> Summary of Utilisation of Proceeds of Preferential issue as on 31.03.2026 <BR> Particulars Rs.In lakhs <BR> Amout Received through Preferential Issue 76,432.53 <BR> Less: Amount Utilised 26,068.64 <BR> Balance Amount 50,363.89 <BR> <BR> 7) Impact of Labour Codes: <BR> On November 21,2025, the government of India notified provisions of the new Labour Code (4 Labour codes) which consolidates 29 existing labour laws into a unified framework governing employee benefit. The labour codes, amongst other things, introduced changes including a uniform definition of wages and enhanced benefits relating to leave. The group has assessed the financial implications of these changes which had resulted in increase in gratuity liability arising out of past service cost by Rs.36.34 lakhs as at 31st Dec,2026 out of total Rs. 61.15 lakhs, for the year ended 31 March,2026. <BR> <BR> The Group is in the process of evaluating the impact of other provisions of the Labour Codes, if any, and will recognise the same as and when such impact becomes reasonably ascertainable. <BR> 8) The figures for the current quarter and quarter ended March 31, 2025 are the balancing figures between the audited figures In respect of full financial year ended March 31, 2026 and March 31, 2025, respectively and published year to date figures upto 3rd quarter ended 31st December 2025 and 31st December 2024, respectively, regrouped as necessary.2025-04-012026-03-31AuditedConsolidated7114700013930100021044800000024149400015780005613500026746820002973889000-27634410000-27634410000000-27634410000000-2763441000-11839000-277528000026372000015650276000-12.13-12.1300-12.13-12.13R & D Expenses423312000Other Expenses39930000R & D Expenses2481881000Other Expenses1928010005570330003596000001447000001802240001802240003880007750520001020000015084000827910003291770000018435470005233192000194920002133840005467088000624214000026372100056502760005913997000591399700000191740001917400003633000444990004813200022334100027147300022259000152370003089690003281430006242140000Right of use Assets171474000Other financial assets8750000Other Non-current Assets388000Investments in mutual funds1806516000Other financial assets37031000Other current assets213384000Lease Liabilities166942000Other Financial Liabilities56399000Other Current liabilities2225900015780001355000-17200000-87108000-388000000-65560000162310000561350000-33870002069000-1037620000242300004240300017869000-9537100000-380000000-246835000-301027600000075910000-301786700000000000050834000000000000000000000424030000-4612707000-46211380000075715410000000000000007571541000-674640000-6746400015025500082791000Items that will not be reclassified to profit or loss-2245000-2245000Items that will not be reclassified to profit or loss-2219000-221900000Items that will be reclassified to profit or loss-2421000-2421000Items that will be reclassified to profit or loss-9620000-962000000-4666000-11839000AuditedtrueKARVY & Co.true2028-04-30